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Abstract: Ageing is the result of changes in biochemical and biophysical processes at the cellular 9 
level that lead to progressive organ decline. Here we focus on the biophysical changes that impair 10 
cellular function of human dermal fibroblasts using donors of increasing age. We find that cell 11 
motility is impaired in cells from older donors, which is associated with increased Young’s 12 
modulus, viscosity and adhesion. Cellular morphology also displays parallel increases in spread 13 
area and cytoskeletal assembly, with a 3-fold increase in vimentin filaments alongside a decrease in 14 
its remodelling rate. Treatments with withaferin A or acrylamide show that cell motility can be 15 
modulated by regulating vimentin assembly. Crucially, decreasing vimentin amount in cells from 16 
older individuals to levels displayed by the neonatal donor rescues their motility. Our results 17 
suggest that increased vimentin assembly may underlay the aberrant biophysical properties 18 
progressively observed at the cellular level in the course of human ageing and propose vimentin as 19 
a potential therapeutic target for ageing-related diseases. 20 
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 23 
1. Introduction 24 
Ageing is a complex process characterised by temporal changes in biological, biophysical and 25 
biochemical function that lead to a progressive whole-body decline throughout the lifespan of an 26 
individual. While age-related deterioration is most conspicuous at the organ level, it has been 27 
hypothesized that the underlying causes are likely to be dysfunctions at the cellular and tissue level 28 
[1]. Age is a risk factor for many pathologies such as cardiovascular disease [2], osteoarthritis [3], 29 
idiopathic pulmonary fibrosis [4], glaucoma [5] and cancer [6]. Possibly due to the links between 30 
pathology and ageing, the majority of ageing research has focused on assessing decline in organ or 31 
tissue function and associating it to changes in genetic, epigenetic or metabolic states. On the other 32 
hand, cellular behaviour integrates as a simpler output the plethora of molecular networks and gene 33 
up/down regulations that define the molecular state of a cell. Accordingly, complex age-associated 34 
perturbations at the molecular level may be more easily captured as aberrations at the cellular level. 35 
In spite of that, a limited number of studies have assessed age-associated changes in cell behaviour.  36 
The majority of cellular studies on ageing have focused on recursive passaging in vitro as a 37 
surrogate of ageing in vivo [7–10]. Conversely, comprehensive studies of single cells isolated from 38 
donors at different ages have been limited, and tend to focus on measuring replicative decline or the 39 
emergence of senescence within a cell population [11]. Recent studies have demonstrated that donor 40 
age can be determined using biophysical biomarkers such as cell migration, contractility,  41 
mechanical properties and gross morphological features [12,13]  It thus follows from those findings 42 
that biophysical properties do change significantly and become aberrant as a result of donor ageing 43 
[14,15], a phenomenon that likely impairs cell function. 44 
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It is often assumed that actin is the main cytoskeletal network involved in the regulation of cell 45 
motility [16,17], the generation of  contractile forces and in overall cell biophysical properties 46 
[18,19]. Recent studies have revealed that microtubules and especially the intermediate filament 47 
vimentin also play a crucial role in functions ranging from cell motility to signal transduction. Of 48 
late, vimentin has been reported to be involved in cell migration by regulating acto-myosin 49 
contraction forces, interactions with the extracellular matrix, and also in the ability of the cell to 50 
move its nucleus forward [20,21]. Other studies have highlighted vimentin’s role in wound healing 51 
by coordinating fibroblast proliferation [22] or in collective cell migration by controlling traction 52 
forces [23]. Interestingly, it has been suggested that vimentin fibres are the major contributor to 53 
cytoplasmic but not cortical stiffness of cells, given that the cytoplasm of wild-type fibroblasts is 54 
2-fold stiffer  than that of their vimentin-deficient counterparts, even though cortical stiffness 55 
remains the same [24]. Vimentin-deficient cells also show defects in cell motility and directionality as 56 
well as a reduction in wound healing capacity [25,26] while overexpression of vimentin promotes 57 
prostate cancer cell invasion and metastasis [27]. Finally, vimentin has also been linked to ageing, 58 
with observations that senescent cells show increased levels of vimentin expression [28] and that 59 
glycation of vimentin is increased in fibroblast from old donors [29]. 60 
In this study, we used a combination of biophysical approaches to assess how cell morphology 61 
and biophysical behaviour are altered due to ageing. Human dermal fibroblast from donors of 62 
different ages were used as a model to characterize how changes in cell motility and biophysical 63 
properties are associated to changes in cytoskeleton organisation. Fibroblast from older donors had 64 
reduced cell motility and increased cell stiffness, which was associated to changes in cytoskeletal 65 
assembly. In particular the age-associated aberrations in cell motility and biophysical properties 66 
appeared alongside vimentin accumulation, and could be rescued using drugs believed to primarily 67 
target vimentin. Our findings suggest the importance of vimentin in donor ageing and point 68 
towards this cytoskeletal protein and associated signaling pathways as a potential biomarkers for 69 
the diagnosis, prognosis and treatment of a wide variety of different diseases associated with ageing. 70 
2. Materials and Methods 71 
2.1. Cell lines and culture 72 
Human dermal fibroblasts were obtained from commercial sources. In brief, cells were derived 73 
from temple or labia tissue from ‘apparently healthy' caucasian female donors. Neonatal (N) and 74 
adult age 62 (A62) cells were purchased from Lonza Biologics, while adult age 21 (A21) and age 47 75 
(A47) cells were purchased from PromoCell. Vials of cells were shipped at passage 2 and all 76 
experiments were carried out in cells up to passage 7. NIH 3T3 cells were a gift from A.Mata group 77 
(Queen Mary University of London). All cell work was conducted in identical conditions among all 78 
donors and culturing of cells was carried out in parallel. Cells were cultured on plastic plates in high 79 
glucose (4.5g/L) DMEM medium (Gibco) supplemented with 10% foetal bovine serum (FBS) (Sigma) 80 
and 1% penicillin/streptomycin.   81 
2.2. Cell transfection 82 
Cells were transfected with actin (pCAG-mGFP-Actin, 21948, AddGene) or vimentin 83 
(pVimetin-PSmOrange, 31922, AddGene) plasmids. Cells were seeded at low density (2,000-5,000 84 
cells/cm2) onto 6-well tissue culture treated plates in antibiotic free medium and allowed to adhere 85 
overnight. After cells were transfected with plasmids using a specific dermal fibroblast transfection 86 
reagent (EZBiosystems). The concentrations of plasmids and reagent was scaled down according to 87 
the number of cells per well. The transfection was allowed for 6 hours and after the fresh antibiotic 88 
free medium was replaced. All live experiments with transfected cells were performed 48 hours after 89 
transfection. 90 
 91 
2.3. Cell migration 92 
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Transfected cells were seeded onto 6-well plate at low density. Prior to imaging, the medium 93 
was replaced with FBS supplemented Flurobrite-DMEM imaging specific medium (Thermofisher) to 94 
reduce background fluorescence and photobleaching. Time-lapse recordings of single cell dynamics 95 
were acquired with a 20x objective by a Lumascope LS720 microscope (Etaluma) at a rate of 1 image 96 
every 10 minute for at least 6 hours. The miniaturized microscope is placed inside the incubator, so 97 
temperature and CO2 concentration are maintained throughout the time-lapse experiment.  98 
For wound healing assays, cells were seeded at 25000 cells/cm2 on 12-well plates with attached 99 
PDMS stencils and incubated for 2 days to confluence. The ‘’wound’’ was initiated by removing the 100 
PDMS stencil and the medium was aspirated and changed with fresh one. Cell migration was 101 
monitored by taking images every 30 minutes for 100 hours.  102 
The algorithm to analyze time-lapse fluorescence videos is based on grey-scale images of the 103 
fluorescent channels and there are two steps: (1) determination of the cell outlines for every frame, 104 
(2) calculation of the positions of cell centroids. Once the position of the cell’s centroid was 105 
determined for each frame, we computed the cell’s instantaneous migration speed and the 106 
persistance of the overall recorded migration path as previously described elsewhere [30]. In brief, 107 
migration persistence is defined as the ratio between net cell displacement (the euclidian distance 108 
between starting and ending centroid positions) and the overall distance travelled by the cell, as 𝑃 =109 
𝑑(𝑋𝑡=0,𝑋𝑡=𝑇)
∑ 𝑑(𝑋𝑡=𝑖,𝑋𝑡=𝑖+1)
𝑇
𝑖=0
. Persistence values are thus unitless and bound between 0 (random migration) and 1 110 
(straight line). For scratch assay experiments, the wound healing area (area not covered by cells) was 111 
calculated at 0, 24, 48, 75 and 99 hours using and ImageJ script.  112 
 113 
2.4. Cell viscoelastic properties with atomic force microscopy 114 
Atomic force microscopy (AFM) was employed to investigate the biophysical properties of 115 
human dermal fibroblasts. The AFM system (NanoWizard4, JPK, Germany) was mounted on a Zeiss 116 
epifluorescence microscope. Images of live, healthy fibroblasts were scanned under liquid 117 
conditions (DMEM medium with 25 mM Hepes supplemented with 10% FBS and 1% 118 
penicillin/streptomycin) at 37oC with the V shaped gold coated silicon nitride cantilevers (Budget 119 
Sensors) with four-sided pyramidal tips in contact mode. The cantilever had a spring constant of 0.06 120 
N/m, length of 200 µm and width of 30 µm. The spring constant of the cantilever was calibrated 121 
using the thermal fluctuations method based on sensitivity calculation on the bare region of the 122 
substrate. Force maps of the cells were taken in quantitative imaging (QI) mode at a resolution of 32 123 
x 32 pixels, using 4000 nm ramp length, 250 µ/s ramp speed and a force setpoint of 2 nN. Using these 124 
conditions, maximum indentation levels reached were ~2 µm, typically on the vicinity of the nucleus 125 
of the softest cells probed. The scan area depended on the cell size, with the maximum attainable 126 
range being 100 x 100 µm2. If the cell exceeded that range, half or a quarter of cell was chosen 127 
including always a portion of the cell nucleus as well as the cell edge (Figure S1).  128 
Biophysical properties such as Young’s modulus (E), viscosity () and non-specific adhesion 129 
work were determined from the force-distance curves. The force distance curves were analysed 130 
using the BECC model for thin adherent cells on a stiff substrate [31], using a pipeline written in 131 
MATLAB as previously described [32]. Determination of Young’s modulus for the cell cytoskeleton 132 
(ECSK) and the cell cortex (Ecort) was based on the approach proposed in Pogoda et al. [33]. In 133 
particular, and after the contact point has been identified, Ecort is obtained by fitting the 134 
force-indentation curve for data points corresponding to indentations <400nm, whereas Ecsk is 135 
obtained by fitting the force-indentation curve for data points corresponding to indentations 136 
>750nm. Cellular viscosity was determined from force distance curves using the method described 137 
by Rebelo et al. [34]. 138 
2.5. Immunofluorescence staining and imaging 139 
Dermal fibroblast samples were prepared by seeding cells at low density (5000 cells/cm2) on 13 140 
mm glass coverslips. The coverslips were coated with type I collagen at 10 µg/ml concentration for 1 141 
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hours at 37oC. After rinsed with PBS, cells seeded and allowed to adhere for 24 hours. For drug 142 
treatment experiments, cells were seeded at the low density 24 hours prior drug treatment. Cells 143 
were treated with 1 µM, 2.5 µM and 5 µM concentration of withaferin A and with 2 mM, 4 mM and 6 144 
mM concentrations of acrylamide for 3 hours. Then cells were fixed with 4% paraformaldehyde 145 
(Sigma) for 20 min, washed with PBS, permeabilized with 0.25% Triton X-100 (Sigma) for 10 min, 146 
washed with PBS, and blocked with PBS supplemented with 3% bovine serum albumin (Sigma) for 1 147 
hour at room temperature.  148 
For the experiments of cell morphology, cytoskeletons, p21, alpha- smooth muscle actin and 149 
nuclear organization, F-actin filaments were stained with TRITC-tagged Phalloidin (1:1000, Sigma 150 
Aldrich) and co-stained with vimentin monoclonal mouse (1:300, Santa Cruz RV202), tubulin 151 
monoclonal rabbit (1:200, Abcam ab4074) or YAP monoclonal mouse (1:200, Santa Cruz sc-101199), 152 
p21 monoclonal rabbit (1:250, Cell Signaling Technology, 2947) or alpha- smooth muscle actin 153 
monoclonal mouse (1:200, Sigma A2547). Subsequently the secondary antibodies were used 154 
anti-mouse Alexa 488 (Thermo Fisher, A21202) and anti-rabbit Alexa 488 (Thermo Fisher, A21206). 155 
After staining, coverslips were mounted on glass slides with Prolong Gold antifade mounting 156 
medium with DAPI (Thermo Fisher) to protect samples from dry out. Fluorescence images of the 157 
fixed cells were obtained using an inverted epifluorescence microscope (Leica DMI4000B) with 158 
x20/0.5 NA objective lens and a CCD camera (Leica DFC300FX). Images were taken only on well 159 
attached and not damaged cells using DAPI, FITC and TRITC channels.  160 
2.6. Single cell cytoskeleton quantification analysis 161 
Our pipeline for single cell quantification of cytoskeleton and nuclear structures has been 162 
described in detail elsewhere [30]. Briefly, the algorithm uses grey-scale fluorescence 163 
immunostaining-based or live-cell images typically obtained on epifluorescence or confocal 164 
microscopes and it follows three independent steps: (1) initial fiber segmentation, (2) fiber 165 
refinement, and (3) determination and subtraction of non-uniform background within the cell 166 
boundaries. The algorithm outputs data at the single cell level, including gross cell morphology 167 
information like cell area, aspect ratio, and stellate factor or cytoskeleton information like fiber 168 
intensity, length and thickness (for detailed descriptions and examples see [30]. To estimate fibre 169 
thickness in arbitrary units (AU), we measured the average pixel intensities for all pixels identified 170 
by the algorithm as belonging to a fibre. We note that in our imaging conditions, the pixel size is 171 
larger than the diffraction limit or the thickness of a single cytoskeletal filament. Accordingly, the 172 
measurement of fluorescence pixel intensity constitutes a good surrogate measure to estimate the 173 
number of individual fluorophores bound to a fibre and thus number of filaments making up a 174 
stress fibre or bundle. To estimate fibre length in microns, we computed the average length of the 175 
identified stress fibres or filaments in a cell in pixels, and converted them to microns using 176 
previously-measured calibration factors matching the imaging conditions used. For nuclear data, the 177 
pipeline uses the DAPI images and provide estimates on the relative volume (compared to 178 
non-adherent conditions), chromatin condensation or Poisson’s ratio. In particular, the algorithm 179 
assumes that the gross morphology of the nucleus can be described as an ellipsoid, and uses changes 180 
in fluorescence pixel intensity along the radial direction of the nucleus to estimate the dimensions of 181 
its 3 semi-axes (for detail see [35]). Note only some of all the parameters output by the pipeline are 182 
used in this manuscript, corresponding to their relevance to the present research question.  183 
2.7. Cell reattachment experiments 184 
The reattachment experiments were carried out using the Lumascope LS720 microscope as 185 
above, using only healthy and well-attached transfected cells. To initiate the reattachment event, 186 
cells were treated with trypsin until they displayed a rounded up shape, but before they were 187 
completely detached. Subsequently, fresh imaging medium was added to the wells and the process 188 
of cell reattachment was imaged. Fluorescence images were recorded every 10 minutes for 6 hours 189 
using a 20x objective.  190 
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2.8. Drug treatments against vimentin 191 
Healthy vimentin-transfected and well attached cells were chosen and imaged for 1 hour prior 192 
drug treatment. Subsequently, Withaferin A (Sigma Aldrich) with concentrations of 1 µM, 2.5 µM 193 
and 5 µM, or acrylamide (Bio-Rad) with concentrations of 2 mM, 4 mM and 6 mM was added and 194 
cells were imaged for 6 additional hours. Images were captured every 10 minutes. Cell velocity was 195 
calculated as described above on the same cells before and after drug treatment. 196 
2.9. Statistical analysis 197 
Statistical analysis was performed using GraphPad Prism 5 software. The t-test was used for the 198 
normally distributed data sets, otherwise, the non-parametric Mann-Whitney U test was adopted. 199 
Statistical significance was reported at p<0.05 (*), p<0.01 (**) and p<0.001 (***) unless otherwise 200 
stated. All experiments were performed using at least three replicates unless otherwise mentioned in 201 
the figure legend. 202 
3. Results 203 
3.1. Donor age reduces cell migration and increases Young’s modulus of human dermal fibroblasts 204 
The purpose of this study was to evaluate the biophysical properties of human dermal 205 
fibroblast cells obtained from donors of different ages, obtained at ages: neonatal, 21, 47 and 62 206 
years. To measure the cell velocity of single cells, a miniaturized live imaging system placed inside 207 
an incubator was used to perform long term cell migration experiments in 2D at physiological 208 
conditions. Cells were seeded at low density onto 6-well plates and transfected separately with a 209 
fluorescently-tagged vimentin plasmid. Transfected cells were allowed to recover for 48 hours prior 210 
to migration experiments. Images were taken only of single cells that were clearly transfected, 211 
healthy and well attached. Time-lapse fluorescence images were taken every 10 minutes for 6 hours. 212 
The videos of cell migration were then analysed to measure migration velocity and directionality, by 213 
tracking the non-fluorescent circular area corresponding to the cell nucleus. The results show that 214 
human dermal fibroblast cells from the neonatal donor have a significantly higher velocity 215 
compared to all adult donors. The largest difference (2-fold) was observed when comparing them to 216 
cells from the oldest donor (Figure 1A). Interestingly, cell persistence was affected only when 217 
comparing cells from the neonatal to the oldest donor (Figure 1B). Scratch assays yielded similar 218 
trends, with the oldest donor showing delayed migration into the scratch, even though no 219 
differences were observed for the other donors (Figure S2). Of note, the rate at which the wound 220 
closes is affected by the migration speed of cells, but also by the average spread area of the cells. 221 
Given that both are affected by donor age, our results measuring individual cell migration thus 222 
constitute a less incumbered method and provide clearer results. To rule out that the observed 223 
differences in cell migration were not due to other differences between the primary cells used, we 224 
quantified nuclear expression of p21, as a marker of cell proliferation, and cytoplasmic expression of 225 
α-smooth muscle actin (α -SMA), as a marker of myogenic differentiation. In both cases, we didn’t 226 
observe clear trends with donor age or cell spread area, but found a slight but significant increase on 227 
p21 nuclear expression for the A62 donor (Figure S3) and a slight but significant decrease in α -SMA 228 
for the A47 donor (Figure S4). Altogether our results suggest that donor age has a significant impact 229 
on cell motility which may delays the capacity of dermal fibroblast to engage in wound healing. 230 
Cell motility is associated with changes in biophysical properties, which are regulated by the 231 
cytoskeleton. We therefore examined whether donor age has an effect on cell biophysical properties 232 
using Atomic force microscopy to measure viscoelastic properties. Individual cells from all groups 233 
were probed in QI mode and our customized data-analysis pipeline was used to calculate cell’s 234 
Young’s modulus (E), viscosity and adhesion work. When determining E, we found that cells from 235 
the oldest donor displayed a 2-fold increase compared to cells from the neonatal donor (Figure 1C). 236 
Similarly, the measurement of cell viscosity showed a significant 1.4-fold increase for cells from 237 
adult donors compared to cells from the neonatal donor (Figure 1D). Furthermore, when evaluating 238 
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cell adhesion work, we found significant differences also between cells from the neonatal donor 239 
compared to cells from the oldest donor, the increase being 1.5-fold (Figure 1E). While previous 240 
studies using immunostaining have demonstrated that adhesion proteins increase in senescent cells 241 
[36], it is worth pointing out that we report here unspecific adhesion values, given they were 242 
determined as adhesion strength between the cell membrane and untreated silicon nitride 243 
cantilevers tips. 244 
 245 
Figure 1. Biophysical properties are altered by donor age. (A) Corresponding plot showing reduced 246 
cell velocity of single fibroblasts on two-dimensional substrates in relation to donor age. Cell 247 
persistence was significantly different only for cells from oldest donor (B). Data plotted from at least 248 
three independent experiments as geometric mean with quartiles, cell number varies between 249 
(50-60).  Cells from aged donors exhibited increased viscoelastic properties compared to cells from 250 
neonatal donor as quantified by significant differences in (C) Young’s modulus, (D) viscosity and (E) 251 
adhesion work estimated using AFM measurement. All data plotted from at least three independent 252 
experiments as geometric mean with quartiles, ** p<0.01, *** p<0.001, Mann Whitney U test. Cell 253 
number varies between 30-90 with ~12 cells per repeat. 254 
Together, our results show that donor age significantly affects biophysical properties, and in 255 
particular induces a reduction in cell motility alongside increased cell elastic modulus, viscosity and 256 
adhesion force. 257 
3.2. Cellular and nuclear morphology of human dermal fibroblasts depend on donor age 258 
Changes in donor aging have been linked to alterations in cellular morphology [37] and hence 259 
we examined whether the observed aberrations in migration and mechanical properties of human 260 
dermal fibroblasts from older donors were associated with changes on their underlying 261 
cytoskeleton. First, cellular and nuclear morphology was quantified from epifluorescence images of 262 
cells labelled with phalloidin for F-actin and DAPI for the nucleus (Figure 2A). Human dermal 263 
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fibroblasts from older donors displayed a significant increase in cell area compared to cells from the 264 
neonatal donor Cell surface area was around 2000 µm2 (CoV = 58%) for cells for the neonatal donor, 265 
while for cells from adult donors, the surface area was larger and ranging from 3000-7000 µm2 (CoV 266 
= 60%), reaching a larger than 2-fold increase when comparing cells from neonatal donor to cells 267 
from oldest donor (Figure 2B). With increasing donor age, cells also underwent changes in their 268 
aspect ratio, from a spindle shape to large solid spread (Figure 2C). Interestingly, the changes in 269 
cellular morphology and specifically the increases in cell spread area had only a weak correlation 270 
with changes in nuclear volume. In this regard, the nucleus volume increased significantly only 271 
when comparing cells from the youngest to the oldest donors (Figure 2D). 272 
 273 
Figure 2. Cells from aged donors exhibited changes in cellular and nuclear morphology. (A) 274 
Represantative epifluorescence images showing increased cell area and F-actin organization of cells 275 
from donors at different age. F-actin labelled with Phalloidin (red), nucleus DAPI (blue). Scale bars 276 
represent 20 µm. (B) Corresponding plot showing the increased cell area of cells from aged donors 277 
compared to neonatal donor. (C) There was a significant decrease in aspect ration of cells from aged 278 
donors (*** p<0.001, Mann Whitney U test). (D) Nucleus relative volume increased for cells from aged 279 
donor (*** p<0.001, Mann Whitney U test). Data plotted from at least three independent experiments 280 
as geometric mean with quartiles, total cell number varied between 282-620, with ~100 cells per 281 
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repeat. (E) Representative epifluorescence images of YAP localisation in cells from neonatal and 282 
adult donors. Cells are labelled, nucleus DAPI (blue), YAP (green). Scale bars represent 20 µm. (F) 283 
Immunostaining analysis showing a significant reduction of ratio of YAP nuclear to cytoplasmic in 284 
cells from aged donors. (G) Corresponding plot showing correlation between YAP localisation to cell 285 
area. Independantly to donor age, in all age groups larger cells have less nuclear YAP. Data is plotted 286 
from three independent experiments and presented as mean values with SD (nonparametric one way 287 
ANOVA test, *** p<0.001). Number of cells ranged between (68-202). 288 
Previous studies have suggested that YAP localization is regulated by cell-matrix interactions 289 
and intracellular tension during cell attachment and spreading [38]. Since our results showed 290 
age-associated changes in cell biophysical properties and specifically in cell spreading area, we 291 
examined whether they would lead to changes in YAP intracellular localization. We cultured cells at 292 
low density and labelled them with phalloidin for F-actin, YAP primary antibody and DAPI for cell 293 
nucleus. In this experiment phalloidin staining was used to readily quantify cell area and we used 294 
imaging protocols as described above. To measure YAP localisation, specifically whether YAP is 295 
localised preferentially in cell nucleus or cytosol, we quantified YAP nuclear to cytosolic ratio as 296 
done by others [39,40]. Representative fluorescence images show that YAP is more concentrated in 297 
the cell nucleus in cells from the neonatal donor compared to cells from older donors (Figure 2E). In 298 
particular, cells from oldest donor show a 1.6-fold reduction in YAP ratio compared to cells from the 299 
neonatal donor (Figure 2F). We next verified whether there was any connection between YAP 300 
localisation and cell area and found that increasing cell areas lead to decreased YAP ratios in a 301 
strongly correlated manner. Surprisingly, the relationship between YAP localization and donor age 302 
appeared to be only secondary, as shown by the strong overlap between data points for all donor 303 
ages in figure 2G. These results suggest that changes in YAP ratio are primarily associated with 304 
changes in cell area, which is on its own regulated by donor age. 305 
3.3. Vimentin rather than F-actin or microtubules is dominantly increased in human dermal fibroblast ageing 306 
The three main cytoskeletons, F-actin, microtubules and the intermediate filament vimentin are 307 
all key players in maintaining cell morphological and biophysical properties. Since our results 308 
indicated that donor ageing modulated cell biophysical properties and morphology, we next 309 
investigated whether this was associated with changes in F-actin, tubulin and the intermediate 310 
filament vimentin. Similar to previous immunostaining experiments, cells were cultured at low 311 
density and then stained with phalloidin for F-actin and primary antibodies against tubulin or 312 
vimentin. Single cells were imaged using epifluorescence microscope equipped with 20x objective. 313 
Quantification algorithms were used to determine cell morphology as well as properties of fibre 314 
architecture and overall organisation. Representative images show that cells from aged donors had 315 
more pronounced actin fibres compared to cells from the neonatal donor (Figure 2A) as well as 316 
similar changes for tubulin and vimentin fibres (Figure 3A). In particular we found a significant 317 
increase in F-actin amount alongside a significant decrease in actin fibre length and thickness in cells 318 
from aged donors compared to cells from neonatal donor (Figure S5, A,B and C). Donor age had an 319 
effect not only on F-actin, but also on vimentin fibre morphology. The results indicate that cells from 320 
older donors have an increased amount of vimentin with longer and thicker fibres (Figure S5, D,E 321 
and F). Similarly, cells from older donors showed increased levels of tubulin amount with shorter 322 
and thicker fibres compared to cells from the neonatal donor (Figure S5, G,H and I). Together, these 323 
data show that donor aging is associated with changes in all three cytoskeletons. We then 324 
normalised our cytoskeletal amount data to account for differences in primary and secondary 325 
antibody affinities that lead to dissimilar amounts of fluorescence intensities being measured for 326 
each stained cytoskeletal protein. When reporting relative changes against the measured 327 
cytoskeletal amount of the neonatal donor, we found that vimentin displayed the largest increase 328 
with donor age (Figure 3, B,C and D). 329 
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 330 
Figure 3. Age has the highest influence on intermediate filaments. (A) Represantative 331 
epifluorescence images showing tubulin and vimentin organization of cells from donors at different 332 
age. Fibres labelled ageinst tubulin and vimentin (green). Scale bars represent 20 µm. Corresponding 333 
plot of three cytoskeletons showing relative changes in (B) fibre amount, (C) fibre length and (D) 334 
fibre thickness. Vimentin is showing the highest changes compared to F-actin and tubulin. Data is 335 
plotted from three independent experiments and normalised to neonatal donor to show the 336 
magnitute of changes. The data of all cytoskeletons with real values are presented in supplementary 337 
figure (S5). 338 
Accordingly, we decided to further focus on the intermediate filament vimentin and explore its 339 
dynamics. To study the dynamics of vimentin fibres in live cells, we developed a single cell 340 
reattachment experiment as follows. Cells at low density were initially transfected with vimentin 341 
plasmid and treated with trypsin for a short period of time until they displayed a rounded up 342 
morphology without being completely detached. Immediately afterwards, trypsin was gently 343 
exchanged with fresh medium and selected cells were imaged with a 20x objective. Images were 344 
taken every 10 minutes for 10 hours. During the reattachment process, changes in cell area and 345 
vimentin fibre dynamics were clearly observed (Movie S1 and S2). We then investigated whether 346 
vimentin fibre remodelling rate during reattachment was affected by donor age. To do so, vimentin 347 
fibre amount was quantified for all the frames in the videos obtained during the reattachment 348 
process. The representative plots of vimentin fibre versus time show that the amount of vimentin 349 
reaches a plateau, whose value increases in cells from older donors (Figure 4A), in a fashion similar 350 
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to the results obtained for immunostaining. To extract additional information about reorganization 351 
dynamics, we fitted our data using a one-phase exponential decay function: 𝑦 = 𝑦0 + (𝑝𝑙𝑎𝑡𝑒𝑎𝑢 −352 
𝑦0) ∙ (1 − exp(−𝑘 ∙ 𝑥)). From the fitted data, we derived parameters such as half life, computed as 353 
1/k; or span, computed as (𝑝𝑙𝑎𝑡𝑒𝑎𝑢 − 𝑦0) . The half-life parameter estimates the dynamics of 354 
vimentin during reattachment, while span estimates the amount of vimentin once the cell has 355 
established full reattachment (Figure 4B). Our results show that vimentin fibre remodelling rate is 356 
faster for neonatal cells (smaller values for half life) and decreases with donor age (Figure 4C). The 357 
span results again agree with immunofluorescence data, which show increased vimentin 358 
steady-state amount in older cells (Figure 4D). 359 
 360 
Figure 4. Vimentin fibre remodeling rate is faster in cells from young donor. (A) Representative plot 361 
shows the temporal changes in vimentin fibre intensity during reattachment time of cells from 362 
different donor ages. (B) An exponential model was used to fit the data and to determine parameters 363 
such  half life and span. (C) There was a statistically significant difference in vimentin fibre 364 
remodeling half life, indicating slower vimenitin remodelling rate for adult cells. (D) The span 365 
indicates that the vimentin fibre amount is higher in adult cells. Data is plotted from at least three 366 
independent experiments and presented as mean values with SD (*** p<0.001, obtained using 367 
Dunnett test against neonatal donor). Cell number varies between (26-35). 368 
3.4. Drug-induced changes in vimentin assembly are correlated with changes in cell motility and Young’s 369 
modulus 370 
Given that cells from older donors displayed reduced motility and increased amount of 371 
vimentin fibres, we next explored whether biophysical properties of cells could be modulated using 372 
drugs believed to primarily affect vimentin assembly. To do so, we used withaferin A and 373 
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acrylamide and monitored single cell migration after treatments with said drugs in neonatal and 374 
adult cells (using 47 year-old donor source). Cells at low density were transfected with 375 
vimentin-GFP for 72 hours prior drug treatment and time lapse fluorescence images were taken only 376 
on transfected and well attached cells. Considering the large variability of single cell motility, we 377 
decided to image the same individual cells before and after drug treatment. Therefore, cells were 378 
imaged for 1 hour before treatment and 3 hours after drug treatment. Cell velocity was measured as 379 
previously described. In parallel, a different set of cells treated with the same drugs were 380 
immunostained with phalloidin for F-actin and primary antibody against vimentin to quantify their 381 
assembly.  382 
First, we investigated the potential effect of withaferin A treatment on cell migration and 383 
vimentin assembly. Withaferin A treatment caused a reduction in cell motility and increased the 384 
amount of vimentin assembled in fibres for cells from the neonatal donor (Figure S6, A,B and C). 385 
Similar results in terms of cell motility and vimentin assembly were observed in cells from the older 386 
donor (Figure S6, D,E and F). Of note withaferin A treatment caused aggregation of vimentin fibres, 387 
which was already observed in previous study [41] as well.  388 
Next we investigated the effect of acrylamide treatment using the same approach as before. 389 
Surprisingly, acrylamide treatment had no effect on cell migration of cells from neonatal donor and 390 
showed a minor effect on vimentin and F-actin fibres assembly (Figure S7, A,B and C). However, a 391 
significant increase in cell motility alongside a significant reduction in vimentin fibres was found for 392 
cells from the aged donor (Figure S7, D,E and F). These results suggest that withaferin A and 393 
acrylamide have an opposite effect on vimentin assembly in our cells, which is partially dependant 394 
on donor age. Therefore, we pooled all results together from withaferin A and acrylamide 395 
treatments using only the two highest dosages. Surprisingly, we found a strong correlation between 396 
relative changes in cell velocity and relative changes in vimentin amount due to drug treatments. In 397 
particular, withaferin A caused a reduction of cell velocity and increased vimentin amount; 398 
meanwhile acrylamide treatment increased cell velocity and reduced vimentin amount (Figure 5A). 399 
To confirm that this effect was primarily associated with changes in vimentin fibres, we verified that 400 
there was no correlation between cell velocity and F-actin relative changes with either withaferin A 401 
or acrylamide treatments (Figure 5B).  402 
 403 
Figure 5. Acrylamide and withaferin A treatments have a reversable effect on dermal fibroblast 404 
migration and vimentin and actin fibres. (A) Corresponding plot showing the increased cell velocity 405 
of cells treated with acrylamide and decreased cell velosity of cells treated with withaferin A, which 406 
correlated with changed in vimentin amount. (B) The plot shows that cell velocity was not correlated 407 
to changes of F-actin amunt. Plots are presented using acrylamide 4 and 6 mM, and withaferin A 2.5 408 
and 5 µM concentrations. The data of all concentrations is presented in supplementary figures 409 
(S6-S7). 410 
Since withaferin A and acrylamide had a modulatory effect on vimentin fibres, which was 411 
observed alongside changes in cell motility, we next investigated whether a similar correlation was 412 
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observed for Young’s modulus (E) and whether those effects depended on the mechanical structure 413 
being probed. Atomic force microscope was employed to measure the viscoelastic properties of cells 414 
treated with withaferin A or acrylamide. Force indentation curves were taken by probing cells 415 
treated with withaferin A or acrylamide after 3 hours. We found that withaferin A treatment 416 
increased ECSK and Ecort of cells from the neonatal donor (Figure S8, A and B), even though significant 417 
differences were only observed for Ecort at the highest concentration. Conversely, withaferin A 418 
treatment had no effect on cells from the adult donor (Figure S8, E and F), suggesting that it was 419 
unable to further stiffen the already reinforced cytoskeleton of old cells. Similarly, we investigated 420 
the effect of acrylamide treatment on E and found that cells from both neonatal and adult donors 421 
showed a significant reduction in ECSK (Figure S8, C and G), while Ecort was not affected for both 422 
donor ages (Figure S8, D and H). This result is not surprising given that the vimentin network is 423 
primarily localized deep in the cell body, whereas actin is the mechanically-dominant structure in 424 
the cell cortex.  425 
Together, these results suggest that there is a significant correlation between ECSK and vimentin 426 
assembly (Figure 6, A and B), which parallels the correlation between cell migration speed and 427 
vimentin assembly. While we find that withaferin A and acrylamide treatments had a mild effect on 428 
actin assembly, this was not correlated with ECSK, Ecort (Figure 6, C and D) or cell migration speed.  429 
 430 
Figure 6. Changes in vimentin but not actin amount modulate ECSK and Ecort. Corresponding plots 431 
of (A) cytoskeleton and (B) cortical stifness show a significant correlation to vimentin amount. Cell 432 
treatments with withaferin A and acrylamide correlate with increased E of cells with higher amount 433 
of vimentin. Changes actin amount in treated cells with not effect cell (C) cytoskeletal and (D) cortical 434 
Young’s modulus. Plots are presented using acrylamide 4 and 6 mM, and withaferin A 2.5 and 5 µM 435 
concentrations. The data of drug treatment and significant differences presented in supplementary 436 
figures (S8). 437 
Accordingly, our findings indicate that for human dermal fibroblasts, cell biophysical 438 
properties such cell motility and Young’s modulus are primarily correlated with amounts of 439 
vimentin assembled in filaments. Specifically, treatments on older cells that lower the amount of 440 
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vimentin to levels comparable to those displayed by younger cells also result in the rejuvenation of 441 
the biophysical and migratory phenotype displayed by older cells. 442 
4. Discussion 443 
In this study, human dermal fibroblast cells from donors of different ages were used as a model 444 
to study how single cell migration, biophysical and morphological properties are altered by donor 445 
age. In recent years, a number of studies have focused on characterizing delays in wound healing 446 
associated with cellular aging [42,43]. In particular, cell velocity is considered a key biophysical 447 
parameter, which is widely used to characterize the cell’s ability to move from a healthy to a 448 
diseased location within its host tissue [44–47]. Previous studies have focused on proteasome 449 
content and activity to understand cell senescence [48], but little is known on how cell biophysical 450 
and morphological properties are associated with donor age. Here, we show that donor aging 451 
resulted in reduction of cell motility, which was associated with cell stiffening and increased 452 
amounts of F-actin, tubulin and dominantly vimentin. 453 
The cytoskeleton is a complex system with a broad range of functions such as the formation and 454 
maintenance of cell morphology, polarity, cell division and migration. Cells from aged donors 455 
displayed changes in cell morphology with a reduction in cell motility and increased mechanical 456 
strength. It is thus expected that the integrity of the cytoskeleton is altered, not only at the 457 
macrostructure but also at the nanostructure level. F-actin fibres are believed to be key factors in 458 
regulating cell shape and motility, although microtubules and intermediate filaments play a crucial 459 
role too. In this connection, changes of F-actin structure and amount have been reported in cells 460 
undergoing induced senescence. For one study, cells had thicker fibres but the total amount of 461 
F-actin remained the same [36]. Meanwhile in another study, the total amount of actin protein was 462 
observed to be reduced in cells from aged donors [49]. Among other cytoskeletal networks, changes 463 
of the intermediate filament vimentin have been reported in several types of senescent cells. Using 464 
extensive passage as a surrogate for cellular aging, vimentin was found to develop thick and long 465 
fibres, while cells at early passage had thin and short fibres [50]. Similarly, it has been reported that 466 
the amount of tubulin fibres also increases in senescent cells [37]. In this study, we report for the first 467 
time that all three cytoskeletons are altered by donor age. F-actin, tubulin and vimentin all increased 468 
in abundance for cells from adult donors, displaying shorter and thinner fibres for F-actin and 469 
tubulin, and longer and thicker fibres for vimentin. Focusing on vimentin as the most reinforced 470 
structure, we found that vimentin fibre remodelling rate is slower, with higher level of protein in 471 
cells from adult donors.  These changes suggest that the increased assembly of vimentin filaments 472 
observed in cells from older donors plays an important role in the aberrant biophysical properties 473 
associated with donor aging. 474 
Yes-associated protein (YAP) has been shown to be regulated by cell senescence [51]. Here, we 475 
show that changes in YAP ratio are most likely primarily associated with changes in cellular gross 476 
morphology (Figure 2G). Therefore, YAP ratio changes are indirectly dependent on donor age, as 477 
cells from aged donors display larger spreading areas that leads to lower YAP ratios. On a different 478 
note, observations by others indicate that senescent cells have larger spread areas [52]. While on 479 
average, the population of cells from the A62 donor displayed a light increase in senescence 480 
(reduced proliferation) marker p21, we didn’t find correlation trends between nuclear expression of 481 
p21 and cell spread area when we performed our analysis on a single-cell basis. Put together, these 482 
suggest that the aberrations in biophysical parameters we observe for cells from older donors are 483 
likely linked to changes in vimentin assembly, rather than being linked to the onset of senescence. Of 484 
note, one a different unpublished study, we find that extensive passaging (more than 15 passages) of 485 
neonatal cells leads to similar biophysical properties to those displayed by early-passage cells from 486 
older donors (data not shown). Conversely, extensive passaging of cells from older donors doesn’t 487 
result in further reinforcement of the cytoskeleton and cell mechanics, but rather leads to an aberrant 488 
mechanical phenotype that may represent the onset of senescence (data not shown). 489 
 Vimentin has been known to play a key role in cell migration. In migrating fibroblasts, the 490 
nucleus is surrounded by an abundance of vimentin filaments, which extend into the tail of the cell. 491 
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On the contrary, vimentin monomers and short filaments are localized at the leading edge. These 492 
intracellular regional changes in vimentin structure and organization are responsible for regulating 493 
protrusion activity. In addition, serum starvation in fibroblasts caused reduced motility and the local 494 
break down of the vimentin network [53]. Similarly, vimentin assembly is essential for wound 495 
healing in several animal models and cells in culture [25,26,54]. Fibroblasts from vimentin-deficient 496 
mouse exhibited a reduction in cell motility, defects in directionality and on their ability to organize 497 
collagen [25,55], while vimentin overexpression caused increased cell motility of breast cancer cells 498 
[56]. These findings indicate that vimentin filaments play an important role not only in cell 499 
mechanical support but also in cell motility and that an exquisite fine tuning of its amount and 500 
organization is required for optimal cell migration. 501 
The contribution of vimentin organization to cell motility and mechanical properties can be also 502 
assessed using drugs against vimentin. Of note, the use of drugs targeting the polymerization of 503 
vimentin monomers into filaments rather than the use of siRNA against vimentin protein expression 504 
is an approach that parallels the use of Cytochalasin D or Latrunculin A against the assembly of 505 
G-actin monomers into F-actin fibres to understand the structural role of stress fibres on cell 506 
mechanics. That being said, the existing biochemical toolkit to target vimentin is still very limited 507 
and not fully characterized. Accordingly, the two gold-standard drugs used in the literature, 508 
Withaferin A and Acrylamide, may also affect other cytoskeletal structures or signaling pathways in 509 
addition to modulating vimentin filament assembly. In our experiments, Withaferin A treatment 510 
induced disruption of vimentin organization and lead to the formation of aggregates, which are 511 
believed to be associated with changes in cell shape, reduction in cell motility [57] and cell softening 512 
[41]. Similarly, cells treated with acrylamide have been reported to display reduced stiffness, as 513 
evaluated by applying large strains on cells embedded in alginate gels [58]. Interestingly, in our 514 
study, we find that cells from both neonatal and adult donors treated with withaferin A at 515 
concentrations of 1 µM – 5 µM displayed reduced cell motility and increased cell stiffness which was 516 
likely associated with aggregation of vimentin. We thus hypothesize that the observed cell stiffening 517 
is associated with changes in vimentin organization from long filaments to short structures and 518 
aggregates. The aggregates then formed solid, stiff structures, which increased cell stiffness. 519 
Furthermore, we find that withaferin A-associated changes in vimentin organization, cell motility 520 
and Young’s modulus are dose and donor-age dependent. In contrast, cells treated with acrylamide 521 
exhibited increased cell motility and reduced Young’s modulus, which was correlated with a 522 
reduction of vimentin assembly. We and others have shown that the modulation in the assembly of 523 
stress fibres, microtubules and intermediate filaments is often analogous and closely tied to cell 524 
spread area [30,35]. It is thus plausible that the drug treatments against vimentin used here did also 525 
induce changes in the assembly of other cytoskeletal filaments. Nevertheless, in our experiments we 526 
used shorter treatments and lower concentrations than those used by others when reporting 527 
detrimental effects of these drugs on all cytoskeletons [59–61]. Similarly, the strong correlation 528 
observed between vimentin assembly and biophysical properties was largely lost when we 529 
performed similar analysis using instead levels of actin filamentous assembly. Together, our results 530 
suggest that in the cellular model used here, vimentin assembly has a dominant role in modulating 531 
the biophysical and migratory behaviours. It is worth mentioning that experiments by others on 532 
vimentin knock-out cells show aberrant biophysical behaviors, with a significant decrease in cellular 533 
stiffness as well as migration speeds [62,63]. Accordingly, we hypothesize that the amount of 534 
vimentin fibrilar assembly, rather than overall level of vimentin protein expression, plays a crucial 535 
role in fine-tuning cell mechanics to attain optimal migration rates. It thus follows that a complete 536 
inhibition of vimentin assembly does not necessary increase cell migration further, and that a certain 537 
amount of vimentin is likely necessary for optimal cell motility.   538 
In summary, and to highlight the relevance of our results, we show that vimentin dominates the 539 
changes in cytoskeleton organization and assembly in human dermal fibroblast cells and may thus 540 
play a key role in the aberrant behaviour and impaired function displayed by this cell type in the 541 
course of human ageing. Accordingly, we propose that vimentin might serve as a suitable 542 
therapeutic target especially for aging-related diseases. We further propose that biophysical 543 
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properties such cell motility and mechanical properties are strongly correlated to vimentin amount 544 
and can thus be readily used as high-throughput biomarkers on drug screening assays in the search 545 
for new anti-aging therapies. 546 
 547 
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